ReviewGut pathogens2025
Fusobacterium nucleatum: a transboundary pathogen in host-microbiota networks.
Review in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Unveiling the Value ofFoods (Basel, Switzerland) · 2026Review
- Screening and dynamic change study of microbial and metabolite markers for calf diarrhea based on multi-omics and machine learning.mSystems · 2026Article
- Metabolic crosstalk between oral microbiota and the host in OSCC: emerging roles of microbial metabolites in tumor initiation and progression.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fusobacterium nucleatum (Fn), a gram-negative anaerobic bacterium,, transitions from oral commensal to systemic pathogen in colorectal cancer (CRC), inflammatory bowel disease (IBD), arthritis, and preterm birth. This review synthesizes Fn's subspecies-specific pathogenic mechanisms. Its virulence factors enable immune evasion, inflammation modulation, and tumor progression. In the gastrointestinal tract, Fn disrupts intestinal barrier integrity through paracellular and apoptotic pathways, activates Th17/ T regulatory (Treg) immune balance alterations, and induces macrophage polarization. Moreover, Fn's role in tumorigenesis involves biofilm formation and metabolic regulation. Within microbial networks, Fn exhibits both synergistic and antagonistic interactions. It collaborates with pathogens like Clostridioides difficile and Pseudomonas aeruginosa to enhance infection, while being inhibited by probiotics such as Lactobacillus rhamnosus and Akkermansia muciniphila. Notably, microbial metabolites like butyrate and hydrogen sulfide display context-dependent roles-some may drive disease progression, while others may suppress it. This comprehensive review highlights Fn's pathogenicity and its complex interactions within microbial communities, offering novel interventions for microbiota-driven pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.